Essex Bio-Technology Limited

1061 · HKEX · Hong Kong

Public Market Listing

1061HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Essex Bio-Technology Limited are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
VEGF-AMonoclonal antibody
Age-Related Macular Degeneration

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 June 2026Topline resultHLX04-OInternational Phase 3 of HLX04-O vs ranibizumab (NCT04740671) met its primary endpoint
Henlius · Source ↗
13 August 2025Filing acceptedHLX04-ONMPA CDE accepts the NDA for HLX04-O (ophthalmic bevacizumab) in wet AMD
CN, NMPA · Shanghai Henlius Biotech · Source ↗
2 April 2025Topline resultHLX04-OChina Phase 3 of HLX04-O vs ranibizumab (NCT05003245) met its primary endpoint
Henlius · Source ↗

Financial reports

No financial reports recorded.